Bottom line
Is PHPSX a good fund? The bottom line
PHPSX is a share class of Pharmaceuticals Ultrasector Profund, a managed health care sector mutual fund from ProShares.
Annual fees run 2.78% — about $278 a year on every $10,000 invested, more expensive than 100% of health care sector funds we track.
It returned +0.4% over one year, +0.7% a year over five years, +1.3% a year over ten (as of Dec 31, 2024, per its prospectus).
With $8.6 million in net assets and 74 holdings, its largest position is N/a (8.2%) and the top 10 make up 39.1% of the portfolio.
What to watch
- Expensive for its category (2.78%)
- 5-year return in the bottom quarter of its category
- 12b-1 marketing fee of 1% a year
- Small fund ($8.6 million) — small funds are likelier to close
- High turnover (178% a year) can mean more taxable distributions
Updated Nov 19, 2026
What PHPSX invests in
Pharmaceuticals UltraSector ProFund (the Fund) seeks daily investment results, before fees and expenses, that correspond to one and one-half times (1.5x) of the daily performance of the S&P Pharmaceuticals Select Industry Index (the Index).
The Fund invests in financial instruments that ProFund Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The Index is designed to measure the performance of pharmaceuticals companies included in the S&P Total Market Index. The S&P Total Market Index is designed to track the broad equity market listed and domiciled in the U.S. The Index includes companies in the pharmaceuticals sub-industry according to the Global Industry Classification Standard (GICS). These companies are then weighted using an equal weight methodology with liquidity adjustments. The Indexs composition and the assigned weights are reevaluated every September with additional weight adjustments in March, June, and December. The Index is constructed and maintained by S&P Dow Jones Indices LLC. More information about the Index can be found using the Bloomberg ticker symbol…
From the fund's prospectus (filed Nov 25, 2025).
PHPSX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| PHPSX | +0.4% | +0.7% | +1.3% |
| Health Care Sector median | +14.5% | +4.2% | +7.9% |
Source: Fund prospectus, as of Dec 31, 2024
What PHPSX costs
On a $10,000 investment, PHPSX's 2.78% expense ratio costs about $278 a year. The prospectus estimates $3,752 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.
PHPSX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | N/a | 8.20% |
| 2 | N/a | 6.31% |
| 3 | N/a | 5.05% |
| 4 | N/a | 5.05% |
| 5 | N/a | 3.95% |
| 6 | Crinetics Pharmaceuticals Inc | 2.60% |
| 7 | Mbx Biosciences Inc | 2.28% |
| 8 | Ataibeckley Inc | 2.03% |
| 9 | Definium Therapeutics Inc | 2.00% |
| 10 | Amylyx Pharmaceuticals Inc | 1.62% |
Source: SEC Form N-PORT, period ended Jul 31, 2026
The top 10 make up 39.1% of the fund. See all top 25 holdings and asset mix →